Home / Catalogue/ Metabolic/ Adipotide

MetabolicIn StockSubQ injection

Adipotide

Peptidomimetic · Pro-apoptotic sequence · Synthetic

Half-life

~2-4h

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

2–4 weeks

Refrigerate at 2-8C

Known For

Experimental fat-loss peptide. Targets blood vessels that supply white adipose (fat) tissue, causing fat cell apoptosis (death). Very potent but carries significant kidney toxicity risk.

Mechanism of Action

Peptidomimetic that targets PROHIBITIN on blood vessels feeding fat tissue, cutting blood supply → fat cell apoptosis. ⚠️ EXPERIMENTAL.

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

No pharmaceutical brand ⚠️ Experimental only Never commercialised

Typical Research Dosage

0.5-1mg/kg per week (highly experimental). Often cited at 0.1-0.5mg/day. Very limited human data.

Vial Duration Guide

2mg vial: highly variable. Very short cycles recommended (2-4 weeks max).

Recommended Vial Size

★ 2mg vials Short cycles only (2-4 wks). 2mg at 0.1-0.5mg/day = 4-20 days ✓. 5mg vial likely won't be used in time.

Time to Effects

EARLY: 1-2 weeks FULL: 2-4 weeks Effects are rapid due to the mechanism (cutting blood supply to fat cells). Visible fat reduction can occur within 2 weeks. ⚠️ However, kidney stress also occurs rapidly. Cycles are kept very short (2-4 weeks max) specifically because of toxicity concerns. Monitor kidney function closely.

Contraindications & Do Not Combine

• Do NOT combine with other nephrotoxic compounds • Caution combining with NSAIDs (compounded kidney stress) • ⚠️ High-risk compound — minimise polypharmacy

Common Side Effects

⚠️ KIDNEY TOXICITY observed in primate studies: renal tubular degeneration, elevated BUN/creatinine. Dehydration.

Drug Interactions

NSAIDs, nephrotoxic drugs (additive kidney damage risk). ACE inhibitors.

Reversibility

Unknown — theoretical fat cell death may be permanent but kidney damage also possible

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Barnhart et al. (2011) Sci Transl Med 3(108). DOI: 10.1126/scitranslmed.3002621 — Targeted obesity therapy in primates • Showed renal toxicity in primate studies • NO HUMAN TRIALS COMPLETED • ⚠️ HIGH RISK — experimental compound

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

2-8°C

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	2–4 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

Adipotide discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$95.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~2-4 hours (estimated)
Delivery	SubQ injection
Typical dose	0.5-1mg
Storage (lyoph.)	2–8°C
Storage (recon.)	2–4 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None known
WADA	Not listed — investigational
FDA status	Preclinical only